Clinical trials: Tamoxifen
Breast Cancer
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen by the tumor cells.
- Trial name
- NCT00016432
- Testing
- exemestane
- Where
- 162 sites in United States, Canada and 1 more
- Volunteers
- 1,598 people
- Sponsor
- NSABP Foundation Inc
Endometrial Cancer
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen.
- Trial name
- NCT00004915
- Testing
- raloxifene
- Where
- United States
- Sponsor
- Northwestern University
Metastatic Breast Cancer
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
The purpose of this study is to determine whether IMC-A12 offers increased progression-free survival (PFS) associated with IMC-A12 monotherapy and IMC-A12 in combination with an antiestrogen therapy in patients with hormone…
- Trial name
- NCT00728949
- Testing
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Eli Lilly and Company
Hypertension, Pulmonary Arterial Hypertension
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH).
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension
- Trial name
- T3PAH (NCT03528902)
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University Medical Center
Glioblastoma, Brain Tumor
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.
- Trial name
- NCT04200066
- Testing
- Temozolomide, Tamoxifen, Maprotiline
- Sponsor
- University of Rochester
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
Early Breast Cancer
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.
- Trial name
- NCT01155063
- Testing
- Aromasin (exemestane)
- Volunteers
- 89 people
- Sponsor
- Pfizer
Breast Cancer
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and…
- Trial name
- NCT05780567
- Testing
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
- Where
- 3 sites in China
- Volunteers
- 1,946 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003035
- Testing
- filgrastim, doxorubicin hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Georgetown University
Vaginal Bleeding
Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial
The purpose of this research study is to evaluate the ability of medicines called tamoxifen or estradiol to prevent annoying vaginal bleeding for arm implant users.
- Trial name
- NCT04933240
- Testing
- Tamoxifen Citrate 10Mg Tab, Estradiol
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Breast Cancer, Angiogenesis
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
Changes in major angiogenic proteins have been seen following initiation of tamoxifen and aromatase inhibitor therapy in women with breast cancer. One source of these proteins is the circulating platelet pool.
- Trial name
- NCT00727948
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Vermont
Breast Neoplasm
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.
- Trial name
- MEGA (NCT03024580)
- Testing
- Megestrol Acetate 160Mg Tablet, Anastrozole 1Mg Tablet, Letrozole 2.5Mg Tablet
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Pancreatic Cyst, Pancreatic Mucinous Cystic Neoplasm
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
Pancreatic mucinous cystic neoplasm (MCN) is a precursor to invasive pancreatic adenocarcinoma which occurs almost exclusively in females in their 5th-7th decade.
- Trial name
- MCN_Tam (NCT06320990)
- Testing
- Tamoxifen 20mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Breast Cancer Female
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
This is an open-label, single arm, phase 2 trial that will include pre or post-menopausal female subjects, that have ER-positive, HER2-negative early breast cancer.
- Trial name
- NeoRHEA (NCT03065621)
- Testing
- Palbociclib
- Where
- 5 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Jules Bordet Institute
Covid19
Selective Estrogen Modulation and Melatonin in Early COVID-19
This study is a randomized, double-blind, controlled clinical trial to evaluate the effects of toremifene and/or melatonin in adults with mild COVID-19.
- Trial name
- SENTINEL (NCT04531748)
- Testing
- Toremifene, Melatonin
- Sponsor
- Reena Mehra, MD
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy or endocrine therapy in patients with HER-2 positive stage I breast cancer.
- Trial name
- IRIS (NCT04383275)
- Testing
- capecitabine and trastuzumab, endocrine therapy and trastuzumab
- Where
- China
- Volunteers
- 367 people
- Sponsor
- Fudan University
Breast Cancer Female
Factors Influencing Tamoxifen Adherence in Women With Breast Cancer Receiving Tamoxifen in Botswana.
Botswana is an ideal location to investigate tamoxifen adherence for numerous reasons. First, in contrast to many other countries in SSA, tamoxifen is affordable and widely available to women with ER+ breast cancer in Botswana.
- Trial name
- TAM (NCT06660030)
- Testing
- No intervention
- Where
- Botswana
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Breast Cancer
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given…
- Trial name
- NCT00002707
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 145 sites in United States, Canada
- Volunteers
- 2,411 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002581
- Testing
- cyclophosphamide, fluorouracil, methotrexate
- Where
- 9 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network